Comparing two antibiotics for staph bloodstream infection
Part of Infections clinical trials.
This trial compares two antibiotics, cloxacillin and benzylpenicillin, to see which works better for patients with a bloodstream infection caused by a specific type of staph bacteria that responds well to penicillin. It may help guide more effective treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a bloodstream infection caused by Staphylococcus aureus bacteria that is susceptible to penicillin.
- You are not allergic to penicillin.
- You can understand and give written consent.
- You do not have a very low white blood cell count (neutropenia) or have been on antibiotics for 96 hours or more.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding linezolid, an antibiotic that stops bacteria from making proteins, to usual care works better for treating Staphylococcus aureus bloodstream infections. You may be eligible if you have this infection and are hospitalized.
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
This trial tests whether switching from IV antibiotics to oral antibiotics after 3–7 days is safe and effective for people with uncomplicated Staphylococcus aureus bloodstream infections. It may help you avoid a longer hospital stay and reduce IV-related complications.
This trial tests the best treatment approach for bloodstream infections caused by Staphylococcus aureus (“S. aureus”). It uses a flexible design to decide which treatment track you fit into, and may help improve recovery while avoiding unnecessary medications.
This trial looks at how well certain penicillin-type antibiotics work for treating a bloodstream infection caused by a bacterium called Enterococcus faecalis. It may help doctors know which treatment is best for patients with this infection.
This trial tests whether piperacillin-tazobactam works as well as meropenem to treat bloodstream infections caused by certain E. coli or Klebsiella germs that resist common cephalosporin antibiotics. It may help you avoid a “bigger” antibiotic if the study drug is equally effective.
Hear when a new Staphylococcus Aureus Bacteraemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.